To include your compound in the COVID-19 Resource Center, submit it here.

Guts and ambition

Why microbiome play Evelo raised $50 million to expand its clinical program

With an additional $50 million in funding and plans to start 5-10 clinical trials of monoclonal microbials in 2018, Evelo Biosciences Inc. is shaping up to be one of the most ambitious of the microbiome companies.
The $50 million series B round announced July 11 brings the company’s

Read the full 476 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE